Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 12:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 133 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Paroxetine Hydrochloride Clear all
Completed Phase 1Phase 2 Interventional

Trial of Paroxetine-CR for the Treatment of Patients With Post Traumatic Stress Disorder Remaining Symptomatic After Initial Exposure Therapy

NCT00121888
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Prolonged Exposure Therapy, Paroxetine-CR
Behavioral · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 72 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 6, 2014 · Synced Oct 8, 2026, 12:59 AM EDT
Recruiting No phase listed Observational

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

NCT03511118
View directory record Official record
Conditions
Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI
Interventions
Tranexamic acid (TXA), labetalol, metformin, nifedipine, clindamycin, oxycodone, azithromycin, escitalopram, sertraline, ondansetron, Ciprofloxacin, Doxycycline, Levofloxacin, Methylphenidate, Sumatriptan, Citalopram, Cyclobenzaprine, Furosemide, Gabapentin, Hydrochlorothiazide, Hydroxyurea, Rosuvastatin, Topiramate, Trazodone, Valganciclovir, Venlafaxine, Verapamil, Remdesivir, Anakinra, Tocilizumab, Fluvoxamine, Amoxicillin, Bupropion, Duloxetine, Hydrocodone, Levetiracetam, Paroxetine, Buprenorphine
Drug
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
20
States / cities
La Jolla, California • Loma Linda, California • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Depression in Parkinson's Disease Trial

NCT00062738
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
paroxetine, Nortriptyline, placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 8, 2026, 12:59 AM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 3 Interventional

Treatment of Panic Disorder: Long Term Strategies

NCT00000368
View directory record Official record
Conditions
Panic Disorder, Agoraphobia
Interventions
Cognitive behavior therapy, Paroxetine or other medication - algorithm used
Behavioral · Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Not applicable Interventional

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

NCT00012558
View directory record Official record
Conditions
Bipolar Disorder
Interventions
lithium, valproate, bupropion, paroxetine, lamotrigine, risperidone, inositol, tranylcypromine, Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythms Therapy
Drug · Behavioral
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
15 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
11
States / cities
Stanford, California • Denver, Colorado • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 4, 2007 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence

NCT00330239
View directory record Official record
Conditions
PTSD
Interventions
Paroxetine CR
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 3, 2007 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Major Depressive Disorder Study In Adults

NCT00049972
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
71
States / cities
Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 4 Interventional Results available

Combination of Paroxetine CR and Quetiapine for the Treatment of Refractory Generalized Anxiety Disorder

NCT00113295
View directory record Official record
Conditions
Anxiety Disorder
Interventions
Continued Paroxetine CR, Quetiapine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 72 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

NCT00031317
View directory record Official record
Conditions
Panic Disorder
Interventions
Paroxetine, Clozapine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals

NCT00178035
View directory record Official record
Conditions
Depression
Interventions
paroxetine, One night of Total Sleep Deprivation
Drug · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 8, 2026, 12:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Structure and Function Before and After Treatment for Post-Traumatic Stress Disorder

NCT00069225
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

NCT01360866
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,944 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
93
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Tinnitus With Migraine Medications

NCT04404439
View directory record Official record
Conditions
Tinnitus, Subjective, Tinnitus
Interventions
Nortriptyline + Topiramate, Verapamil + Paroxetine, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
25 Years to 85 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 4 Interventional

Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression

NCT00178100
View directory record Official record
Conditions
Unipolar Depression
Interventions
Interpersonal Psychotherapy, paroxetine
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
69 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 3 Interventional

Depression Study In Elderly Patients

NCT00067444
View directory record Official record
Conditions
Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions
Paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
46
States / cities
Little Rock, Arkansas • Anaheim, California • Beverly Hills, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Incorporating Patient Treatment Choice to Improve Treatment Retention in Depressed Hispanics

NCT00742573
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Antidepressants through Texas Medication Algorithm (TMA), Brief Interpersonal Psychotherapy (IPT-B)
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 79 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Paroxetine Hydrochloride Tablets 40 mg and Paxil® Tablets 40 mg

NCT00648193
View directory record Official record
Conditions
Healthy
Interventions
Paroxetine hydrochloride 40 mg tablet, Paxil® 40 mg Table
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 2 Interventional

A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder

NCT00273039
View directory record Official record
Conditions
Social Anxiety Disorder, Anxiety Disorders
Interventions
paroxetine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
14
States / cities
Beverly Hills, California • Burbank, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2015 · Synced Oct 8, 2026, 12:59 AM EDT
Terminated Phase 1 Interventional Results available

Piloting Acute Care to Primary Care Linkage of Safety Net Patients

NCT01347541
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy, Motivational Interviewing, FDA-Approved Anti-Anxiety Medications, Standard Care Control
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 8, 2026, 12:59 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

NCT00797966
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
OPC-34712, Placebo, ADT
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
50
States / cities
Arcadia, California • Beverly Hills, California • Escondido, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 8, 2026, 12:59 AM EDT